Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Bronchial carcinoma: added benefit of crizotinib for first-line treatment not proven

2016-04-01 In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive.  read more Link to "Bronchial carcinoma: added benefit of crizotinib for first-line treatment not proven"

Genvoya in HIV: Positive effects predominate in some adults, negative effects in others

2016-04-01 There is a hint of a minor added benefit for pretreated women, and a hint of lesser benefit for treatment-naive adults.  read more Link to "Genvoya in HIV: Positive effects predominate in some adults, negative effects in others "

Efmoroctocog alfa for haemophilia A: added benefit not proven

2016-04-01 No added benefit can be derived from the dossier: The study pool for the historical comparison conducted and the information on results were incomplete.  read more Link to "Efmoroctocog alfa for haemophilia A: added benefit not proven"

Sacubitril/valsartan in chronic heart failure: indication of considerable added benefit

2016-04-01 The new fixed-dose combination has advantages over enalapril regarding mortality, heart failure hospitalizations and quality of life.    read more Link to "Sacubitril/valsartan in chronic heart failure: indication of considerable added benefit"

HIV-positive children and adolescents: added benefit of rilpivirine not proven

2016-04-01 Drug manufacturer only presented data from a one-arm study, which are unsuitable for the derivation of an added benefit in comparison with the comparator therapy.  read more Link to "HIV-positive children and adolescents: added benefit of rilpivirine not proven"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
A10-03 Aromatase inhibitors in female breast cancer on the preliminary report 2016-05-09
D15-01 Optical coherence tomography (OCT) for neovascular age-related macular degeneration as well as diabetic retinopathy with macular oedema on the report plan 2016-05-03

Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Secukinumab (Cosentyx) for ankylosing spondylitis

Secukinumab (trade name: Cosentyx) has been approved since November 2015 for the treatment of ankylosing spondylitis (also known as Bekhtherev disease). The drug is an option for people who did not benefit enough from a conventional therapy.  read more (Link to "Secukinumab (Cosentyx) for ankylosing spondylitis" – opens in a new window)

to top

Glossary entries